Monday, May 29, 2023
HomeBusinessWarburg and Advent in the lead to acquire Baxter's biopharma unit -...

Warburg and Advent in the lead to acquire Baxter’s biopharma unit – Reuters News Agency


- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Business & FinanceDeals

Reuters was first to report on Sunday that a private equity consortium comprising Warburg Pincus and Advent International was in advanced talks to acquire medical device maker Baxter International Inc’s BAX.N biopharma solutions business in a deal that could exceed $4 billion. Warburg Pincus and Advent submitted the most attractive offer to Baxter in an auction that drew interest from other private equity firms as well as major players in the biomedical sector such as Thermo Fisher Scientific Inc. The Reuters scoop has since been confirmed by Baxter.

Market Impact

The deal could reach or exceed $4 billion. 

Article Tags

Topics of Interest: Business & FinanceDeals

Type: Reuters Best

Sectors: Business & Finance

Regions: Americas

Countries: United States

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Source link

Related articles


Please enter your comment!
Please enter your name here

Latest posts

Latest posts